| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font

Show document

Title:Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor
Authors:Smrdel, Uroš (Author)
Popović, Mara (Author)
Zwitter, Matjaž (Author)
Boštjančič, Emanuela (Author)
Zupan, Andrej (Author)
Kovač, Viljem (Author)
Glavač, Damjan (Author)
Bokal, Drago (Author)
Jerebic, Janja (Author)
Files:.pdf Radiology_and_Oncology_2016_Smrdel_et_al._Long-term_survival_in_glioblastoma_methyl_guanine_methyl_transferase_(MGMT)_promoter_methylati.pdf (556,97 KB)
URL http://www.degruyter.com/view/j/raon.2016.50.issue-4/raon-2015-0041/raon-2015-0041.xml
Work type:Scientific work (r2)
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Abstract:Background: In spite of significant improvement after multi-modality treatment, prognosis of most patients with glioblastoma remains poor. Standard clinical prognostic factors (age, gender, extent of surgery and performance status) do not clearly predict long-term survival. The aim of this case-control study was to evaluate immuno-histochemical and genetic characteristics of the tumour as additional prognostic factors in glioblastoma. Patients and methods: Long-term survivor group were 40 patients with glioblastoma with survival longer than 30 months. Control group were 40 patients with shorter survival and matched to the long-term survivor group according to the clinical prognostic factors. All patients underwent multimodality treatment with surgery, postoperative conformal radiotherapy and temozolomide during and after radiotherapy. Biopsy samples were tested for the methylation of MGMT promoter (with methylation specific polymerase chain reaction), IDH1 (with immunohistochemistry), IDH2, CDKN2A and CDKN2B (with multiplex ligation-dependent probe amplification), and 1p and 19q mutations (with fluorescent in situ hybridization). Results: Methylation of MGMT promoter was found in 95% and in 36% in the long-term survivor and control groups, respectively (p < 0.001). IDH1 R132H mutated patients had a non-significant lower risk of dying from glioblastoma (p = 0.437), in comparison to patients without this mutation. Other mutations were rare, with no significant difference between the two groups. Conclusions: Molecular and genetic testing offers additional prognostic and predictive information for patients with glioblastoma. The most important finding of our analysis is that in the absence of MGMT promoter methylation, longterm survival is very rare. For patients without this mutation, alternative treatments should be explored.
Keywords:glioblastoma, long-term survival, methyl guanine methyl transferase, prognostic factor
Number of pages:str. 394-401, V
Numbering:št. 4, Letn. 50
ISSN on article:1318-2099
COBISS_ID:288609792 Link is opened in a new window
DOI:10.1515/raon-2015-0041 Link is opened in a new window
License:CC BY-NC-ND 4.0
This work is available under this license: Creative Commons Attribution Non-Commercial No Derivatives 4.0 International
Average score:(0 votes)
Your score:Voting is allowed only for logged in users.
AddThis uses cookies that require your consent. Edit consent...

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and Oncology
Shortened title:Radiol. Oncol.
Publisher:De Gruyter Open
COBISS.SI-ID:32649472 New window

Secondary language

Keywords:glioblastom, zdravljenje, napovedni dejavniki, genetski označevalci


Leave comment

You have to log in to leave a comment.

Comments (0)
0 - 0 / 0
There are no comments!

Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica